Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors

Cancer Gene Therapy

Volumn 12, Issue 12, 2005, Pages 947-953

  Heinkelein, Martin ^a   Hoffmann, Ursula ^a   Lücke, Markus ^a   Imrich, Horst ^a   Müller, Justus G ^a   Meixensberger, Jürgen ^b   Westphahl, Martin ^c   Kretschmer, Axel ^d   Rethwilm, Axel ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BAYER AG   (Germany)

Author keywords

Foamy virus vector; Oncolytic viruses; Prodrug activation; Suicide gene therapy

Indexed keywords

DNA; GANCICLOVIR; NITROREDUCTASE; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPLICATION; GENE THERAPY; GENETIC TRANSDUCTION; GLIOBLASTOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE; TUMOR MODEL; WILD TYPE;

ANIMALIA; HUMAN SPUMARETROVIRUS; MUS MUSCULUS;

EID: 27744482203     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700855     Document Type: Article

References (29)

1. Culver KW, Ram Z, Wallbidge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
2. Klatzmann D, Valéry CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type I thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum Gene Ther. 1998;9:2595-2604.
3. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 1997;3: 1354-1361.
4. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med. 2002;8:S68-S73.
5. Kirn D. Oncolytic virotherapy as a novel treatment platform for cancer. Ernst Schering Res Found Workshop. 2003;43:89-105.
6. Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002;2: 938-950.
7. Solly SK, Trajcevski S, Frisen C, et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 2003;10: 30-39.
8. Rethwilm A. The replication strategy of foamy viruses. Curr Top Microbiol Immunol. 2003;277:1-26.
9. Falcone V, Schweizer M, Neumann-Haefelin D. Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol. 2003;277:161-180.
10. Lindemann D, Heinkelein M, Rethwilm A. Aspects of foamy virus vectors: host range and replication-competent vectors. In: Cid-Arregui A, García-Carrancá A eds. Viral Vecotrs Basic Science and Gene Therapy. Natick, MA: Eaton Publishing; 2000: 515-522.
11. Trobridge G, Russell DW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol. 2004;78:2327-2335.
12. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foamy retrovirus infection. J Virol. 1995;69: 7295-7299.
13. Heneine W, Schweizer M, Sandstrom P, Folks T. Human infection with foamy viruses. Curr Top Microbiol Immunol. 2003;277:181-196.
14. Epstein MA. Simian retroviral infections in human beings. The Lancet (Correspondence). 2004;364:137-140.
15. Schmidt M, Herchenröder O, Heeney J, Rethwilm A. Long terminal repeat U3 length polymorphism of human foamy virus. Virology. 1997;230:167-178.
16. Baunach G, Maurer B, Hahn H, Kranz M, Rethwilm A. Functional analysis of human foamy virus accessory reading frames. J Virol. 1993;67:5411-5418.
17. Schmidt M, Rethwilm A. Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology. 1995;210:167-178.
18. Nestler U, Heinkelein M, Lücke M, et al. Foamy virus vectors for suicide gene therapy. Gene Ther. 1997;4: 1270-1277.
19. Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual. 3rd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
20. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. New York, NY: John Wiley; 1987.
21. Bigner DD, Bigner SH, Ponten J, et al. Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol. 1981;40:201-229.
22. Westphal M, Hansel M, Hamel W, Kunzmann R, Holzel F. Karyotype analyses of 20 human glioma cell lines. Acta Neurochir. 1994;126:17-26.
23. Montgomery JA, Hewson K. Analogs of 6-methyl-9-beta-D- ribofuranosylpurine. J Med Chem. 1968;11:48-52.
24. Schmidt M, Niewiesk S, Heeney J, Aguzzi A, Rethwilm A. Mouse model to study the replication of primate foamy viruses. J Gen Virol. 1997;78:1929-1933.
25. Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994;13:928-933.
26. Rethwilm A. Foamy Viruses. In: Mahy B, ter Meulen V, eds. Topley and Wilson's Microbiology and Microbial Infections. 10th edn, Virology, London: Arnold; 2005.
27. Switzer WM, Bhullar V, Shanmugam V, et al. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol. 2004;78:2780-2789.
28. Wolfe ND, Switzer WM, Carr JK, et al. Naturally acquired simian retrovirus infections in central African hunters. Lancet. 2004;363:932-937.
29. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. AIDS. 2000;287:607-614.